Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 8.7% – Should You Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares shot up 8.7% on Thursday . The company traded as high as $9.43 and last traded at $9.5350. 77,501 shares traded hands during trading, a decline of 64% from the average session volume of 212,775 shares. The stock had previously closed at $8.77.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Citigroup lifted their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $21.13.

Telix Pharmaceuticals Stock Up 8.4%

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The company’s 50 day simple moving average is $10.03 and its 200 day simple moving average is $8.71.

Insider Buying and Selling

In other news, CEO Christian Behrenbruch bought 33,435 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average price of $14.87 per share, with a total value of $497,178.45. Following the completion of the purchase, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. This trade represents a 0.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On Telix Pharmaceuticals

Large investors have recently bought and sold shares of the company. Rhumbline Advisers increased its stake in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth $89,000. Bank of America Corp DE increased its position in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. OLD Mission Capital LLC bought a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth $111,000. Finally, XY Capital Ltd bought a new stake in Telix Pharmaceuticals in the 1st quarter valued at $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.